Huadong Medicine

Huadong Medicine Co., Ltd. (stock code: 000963) was founded in 1993, with its headquarters in Hangzhou, Zhejiang, and was listed on the Shenzhen Stock Exchange in December 1999. After more than 30 years of development, the company's business covers the entire pharmaceutical industry chain, with four major business segments: pharmaceutical industry, pharmaceutical distribution, medical aesthetics, and industrial microbiology, and has grown into a large comprehensive pharmaceutical listed company integrating innovative drug R&D, production, and distribution.
The pharmaceutical industry segment of the company is deeply engaged in the R&D, production, and sales of specialized drugs, drugs for chronic diseases, and special-use drugs. It possesses a comprehensive pharmaceutical manufacturing system oriented towards the international market, forming core product lines focused on chronic kidney disease, immunology, oncology, endocrinology, digestive system, and cardiovascular diseases. It also has multiple first-line clinical drugs with market advantages domestically, and several products have obtained international registration certifications. Through independent development, external introduction, and project cooperation, the company focuses its innovative drug R&D layout on three core therapeutic areas: endocrinology, autoimmune diseases, and oncology. It has built a differentiated innovative drug pipeline covering the entire R&D cycle and a well-structured product ladder. The company maintains R&D collaborations with multiple international innovative R&D enterprises and has established strategic product cooperation relationships with global multinational pharmaceutical companies in the Chinese market.
The pharmaceutical distribution segment focuses on three core sectors: pharmaceuticals, medical devices, and herbal decoction pieces. With an intelligent logistics network as its foundation, it strengthens its competitiveness through specialized logistics such as cold chain, special drugs, and vaccines, and its business scale firmly ranks first in Zhejiang Province. The pharmaceutical sector has comprehensive advantages in full product coverage, full channel access, efficient linkage between hospital and retail, and deep coordination between distribution and agency. The medical device sector relies on a large-scale distribution network to support professional agency services, focusing on innovative businesses. The herbal decoction pieces sector has advantages across the entire industry chain and continues to expand its provincial business through upgrades, efficiency improvements, and capacity expansion. The company uses digitalization and innovative services as its core drivers, integrating CSO cooperation, SPD supply chain management, and industry-university-research projects to build a "comprehensive pharmaceutical service" ecosystem that precisely links upstream and downstream demands. At the same time, it focuses on three strategic pillars: organizational efficiency improvement, cost control, and regional deepening, to continuously consolidate its industry position.
The medical aesthetics business aims to "build a global top medical aesthetics enterprise," adhering to the strategy of "global operation layout, dual-cycle business development." With an international perspective and forward-looking planning, it creates a comprehensive and differentiated product matrix. Its product variety and coverage fields rank among the top in the industry, achieving integration of "non-invasive + minimally invasive" technologies, "face + body" parts, and "injectables + energy-based devices." In injectables, it achieves full coverage of regenerative, hyaluronic acid, and botulinum toxin categories, forming a differentiated pipeline, providing professionals, safe, effective, and comprehensive solutions for beauty seekers, and striving to become the world's top provider of comprehensive medical aesthetics solutions.
The industrial microbiology sector focuses on two strategic directions: synthetic biology technology innovation and upgrade of the biomedical industry, with emphasis on four core business sectors: xRNA raw materials, specialty APIs & intermediates, health & biomaterials, and animal health. Over forty years of accumulation, the company has formed a research matrix with China Meheco East China industrial microbiology R&D as the core, linked with Huadong Synthetic Biology Industrial Technology Research Institute, Huida Bio, and Shengji Materials, possessing the entire chain of microbial engineering technology. It has established a complete R&D and production system covering the full life cycle of microbial drugs and built an interdisciplinary R&D platform and industrial resource network. In terms of industrial layout, seven production bases—Hangzhou Xiangfuqiao Base, Qiantang New Area, Jiangsu Jiuyang, Hubei Meiqi, Anhui Meihua, Wuhu Huaren, and Nanjing Agricultural Animal Medicine—operate synergistically, equipped with Zhejiang Province's large single fermentation workshops and industry-advanced intelligent production systems, comprehensively covering full-process coverage from strain screening, process development to large-scale production. It has built a complete manufacturing ecosystem chain encompassing technology R&D, pilot-scale scale-up, engineering transformation, and quality control, maintaining its industry position in fermentation scale and process level.